The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
LLM 2021 | Moving CAR T-cell therapy and bispecific antibodies in the consolidation setting
Ruben Niesvizky, MD, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, discusses future strategies for consolidation therapy in multiple myeloma. Prof. Niesvizky explains that novel therapies including bispecific antibodies and chimeric antigen receptor (CAR) T-cell therapy that have shown high efficacy in relapsed/refractory disease could potentially be used as an alternative to stem cell transplantation in the consolidation setting. This interview took place at the Lymphoma, Leukemia & Myeloma Congress 2021.
